secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2026-05-11T20:11:11+00:00
Accession:  0001703057-26-000027
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera reports Q1 net loss $43.2M; positive Phase 1 data for ABCL635 supports monthly dosing
--------------------------------------------------------------------------------

- Net loss of $43.2M ($0.14 loss per share) vs $45.6M loss in Q1 2025; revenue $8.3M up from $4.2M.
- Total available liquidity ~$655M ($531M cash + $124M non-dilutive government funding).
- ABCL635 Phase 1: favorable tolerability, no liver toxicity; half-life ~24 days supports monthly subcutaneous dosing.
- ABCL635 showed sustained dose-dependent suppression of testosterone, a validated NK3R biomarker.
- Partner-led programs with downstreams: 40 (down from 44); 14 molecules in clinic unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000027/0001703057-26-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000027/abcl-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001703057-26-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer